This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.

The present invention relates to monobactam compounds of Formula I:

##STR00001##

and pharmaceutically acceptable salts thereof. The present invention also relates to compositions which comprise a monobactam compound of structural formula I or a pharmaceutically acceptable salt therof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of structural formula I, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

The present invention relates to monobactam compounds of Formula I:

##STR00001##

and pharmaceutically acceptable salts thereof. The present invention also relates to compositions which comprise a monobactam compound of structural formula I or a pharmaceutically acceptable salt therof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of structural formula I, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

The disclosure relates to selective small molecule dual activators of human constitutive androstane receptor (hCAR) and nuclear factor erythroid 2-related factor 2 (Nrf2), pharmaceutical compositions thereof, and use thereof for the treatment of hematologic malignancies and other cancers. The small molecule dual hCAR and Nrf2 activators in combination with CPA based chemotherapy regimen provides a synergistic effect to help promote cytoxicity of the cyclophosphamide (CPA) based and doxorubicin (DOX) based anticancer treatments including CHOP regimen (CPA, doxorubicin, vincristine, and prednisone) while reducing cardiotoxicity associated with DOX.

The disclosure relates to selective small molecule dual activators of human constitutive androstane receptor (hCAR) and nuclear factor erythroid 2-related factor 2 (Nrf2), pharmaceutical compositions thereof, and use thereof for the treatment of hematologic malignancies and other cancers. The small molecule dual hCAR and Nrf2 activators in combination with CPA based chemotherapy regimen provides a synergistic effect to help promote cytoxicity of the cyclophosphamide (CPA) based and doxorubicin (DOX) based anticancer treatments including CHOP regimen (CPA, doxorubicin, vincristine, and prednisone) while reducing cardiotoxicity associated with DOX.

The present invention relates to methods of treating, delaying the onset of, slowing the progression of, or reducing the severity of age-related diseases by administering a compound of Formula 1 to a subject in need thereof. The invention further relates to methods of treating, delaying the onset of, slowing the progression of, or reducing the severity of premature aging disorders by administering a compound of Formula 1 to a subject in need thereof.

The present invention relates to methods of treating, delaying the onset of, slowing the progression of, or reducing the severity of age-related diseases by administering a compound of Formula 1 to a subject in need thereof. The invention further relates to methods of treating, delaying the onset of, slowing the progression of, or reducing the severity of premature aging disorders by administering a compound of Formula 1 to a subject in need thereof.

Compound of formula (I) or pharmaceutically acceptable stereoisomers and/or salts thereof, alone or in combination with quinupristin or pharmaceutically acceptable salts thereof, for use in the treatment of tumors,

##STR00001##

Compound of formula (I) or pharmaceutically acceptable stereoisomers and/or salts thereof, alone or in combination with quinupristin or pharmaceutically acceptable salts thereof, for use in the treatment of tumors,

##STR00001##

Compound of formula (I) or pharmaceutically acceptable stereoisomers and/or salts thereof, alone or in combination with quinupristin or pharmaceutically acceptable salts thereof, for use in the treatment of tumors,

##STR00001##